Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	238.55	104.86	71.43	348.61	71.79	66.42
Short-Term Investments	-	307.49	114.82	-	-	-
Cash & Short-Term Investments	238.55	412.35	186.24	348.61	71.79	66.42
Cash Growth	-51.01%	121.41%	-46.58%	385.59%	8.09%	4.03%
Accounts Receivable	-	-	-	0.35	1.46	0.33
Other Receivables	-	0.56	0.85	5.77	15.7	9.86
Receivables	-	0.56	0.85	6.12	17.16	10.19
Prepaid Expenses	7.59	10.52	2.62	1.5	7.16	9.55
Restricted Cash	0.32	0.33	-	300	-	-
Other Current Assets	-	-	-	0.49	1.2	1.52
Total Current Assets	246.47	423.75	189.71	656.71	97.31	87.67
Property, Plant & Equipment	6.23	7.4	6.06	5.08	3.48	1.28
Goodwill	2	1.86	1.89	1.8	2.01	2.03
Other Intangible Assets	-	-	-	-	10.4	11.52
Other Long-Term Assets	7.03	2.55	5.28	0.58	0.17	-
Total Assets	261.73	435.56	202.95	664.17	113.37	102.5
Accounts Payable	22.25	4.64	2.67	0.36	4.37	6.14
Accrued Expenses	38.01	31.53	14.21	16.31	11.32	4.26
Current Portion of Long-Term Debt	-	-	-	19.77	-	-
Current Portion of Leases	2.72	3.77	2.81	1.69	1.09	0.39
Current Unearned Revenue	-	-	-	-	7.94	8.37
Other Current Liabilities	1.96	1.8	0.72	0.66	0.9	0.73
Total Current Liabilities	64.93	41.73	20.41	38.78	25.62	19.89
Long-Term Debt	-	-	100	494.54	-	-
Long-Term Leases	2.71	3.45	3.29	2.76	1.69	0.08
Long-Term Unearned Revenue	-	-	-	-	-	0.57
Other Long-Term Liabilities	1.83	1.63	1.56	1.43	2.78	2.51
Total Liabilities	69.47	46.81	125.26	537.51	30.09	23.05
Common Stock	7.44	7.38	7.02	2.11	0.98	0.83
Additional Paid-In Capital	2,263	1,598	1,066	504.77	384.05	293.37
Retained Earnings	-2,075	-1,215	-993.26	-378.33	-299.55	-210.95
Comprehensive Income & Other	-2.71	-2.29	-2.45	-1.89	-2.2	-3.79
Shareholders' Equity	192.26	388.75	77.69	126.65	83.28	79.45
Total Liabilities & Equity	261.73	435.56	202.95	664.17	113.37	102.5
Total Debt	5.43	7.22	106.1	518.76	2.78	0.47
Net Cash (Debt)	233.13	405.13	80.14	-170.16	69.01	65.95
Net Cash Growth	-48.70%	405.51%	-	-	4.63%	4.77%
Net Cash Per Share	0.31	0.56	0.13	-0.88	0.75	0.95
Filing Date Shares Outstanding	744.44	737.68	701.7	697.69	98.12	82.92
Total Common Shares Outstanding	744.44	737.63	701.66	211.09	98.04	82.58
Working Capital	181.54	382.02	169.31	617.93	71.69	67.78
Book Value Per Share	0.26	0.53	0.11	0.60	0.85	0.96
Tangible Book Value	190.26	386.88	75.8	124.86	70.88	65.91
Tangible Book Value Per Share	0.26	0.52	0.11	0.59	0.72	0.80
Machinery	-	1.05	0.92	1.39	1.37	1.56
Leasehold Improvements	-	0.32	0.33	0.81	0.37	0.29

Updated Oct 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q